ArticleDiscover nano2026
Development and evaluation of glycine conjugated polypropyleneimine dendrimers for targeted chloroquine delivery.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the synthesis and evaluation of glycine-conjugated 5.0G polypropyleneimine dendrimers as an advanced nanocarrier system for the selective delivery of chloroquine. 5.0G PPI dendrimers were synthesized via a divergent method and subsequently conjugated with glycine. Comprehensive characterization confirmed the successful modification and an increase in nanocarrier size. Drug loading studies demonstrated a significantly enhanced entrapment of chloroquine (57.5% vs. 44.5%) in glycine-conjugated formulations, attributed to the potential complexation and sealing of dendritic branches. In vitro release profiles revealed a substantial reduction in chloroquine release from the glycine-coated dendrimers, indicating a sustained-release capability crucial for prolonged therapeutic action (only 32.07% release over 24 h compared to 88.80% from uncoated). Crucially, macrophage uptake studies indicated a four-fold reduction in phagocytic uptake of glycine-conjugated formulations, suggesting an effective bypass of macrophage recognition, thereby potentially minimizing non-specific clearance. In vivo pharmacokinetic analyses in rats showed a prolonged plasma concentration of chloroquine with the glycine-conjugated system, extending detectability up to 11 h. Furthermore, organ distribution studies highlighted a remarkable increase in liver accumulation (45.6% of the initial dose) compared to uncoated dendrimers or free drug, indicating highly effective liver targeting. These findings highlight the significant potential of glycine-conjugated PPI dendrimers to achieve highly efficient and sustained targeted drug delivery, particularly to the liver, while simultaneously reducing macrophage-mediated clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.